ArticleFrontiers in pediatrics2025
Global burden and epidemiological trends of paediatric-onset multiple sclerosis: a cross-sectional analysis of the 2021 global burden of disease study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paediatric-onset Multiple Sclerosis (POMS) is a rare autoimmune disorder of the central nervous system, primarily affecting children and adolescents, characterized by recurrent episodes of neurological impairment. This study delineates the global disease burden and epidemiological characteristics of this condition. Methods: Data on POMS were obtained from the 2021 Global Burden of Disease (GBD) Study, including estimates from 1990 to 2021. We described the global burden of POMS using incidence, prevalence, DALYs (Disability-Adjusted Life Years), YLDs (Years Lived with Disability), and age-standardized rates. We utilized the Joinpoint Regression Program to analyze the epidemiological trends of POMS disease burden over the past three decades. The Nordpred model was employed to project the future disease burden of POMS. Results: In 2021, the global incidence number of POMS was 1,899 (95% CI: 1,096-2,868), with an ASIR of 0.09 (95% CI: 0.05-0.14). The global prevalence number of POMS was 5,276 (95% CI: 2,921-7,880), with an ASPR of 0.25-95% CI: 0.14-0.38). The global DALYs for POMS was 3,073 (95% CI: 2,216-4,142), with an age-standardized DALYs rate of 0.15 (95% CI: 0.10-0.20). The global YLDs for POMS was 1,489 (95% CI: 737-2,529), with an age-standardized YLDs rate of 0.07 (95% CI: 0.03-0.12). Using Joinpoint Regression, we found that during 1990-2021, the AAPC for global ASIR was 0.07 (95% CI: 0.06-0.07), for global ASPR was 0.05 (95% CI: 0.05-0.05), for global age-standardized DALYs rate was -0.31 (95% CI: -0.34 to -0.28), and for global age-standardized YLDs rate was 0.05 (95% CI: 0.05-0.05). According to the Norpred model, by 2046, the global incidence number of POMS is projected to be 1,760 with an ASIR of 0.14. The global prevalence number of POMS is projected to be 4,915 with an ASPR of 0.38. The global DALYs number of POMS is projected to be 2,694 with an age-standardized DALYs rate of 0.21. The global YLDs number of POMS is projected to be 1,387 with an age-standardized YLDs rate of 0.11. Conclusion: POMS is characterized by a relatively low disease burden; however, it has shown a persistent upward trend in recent years. It is necessary to increase focus on this disease and develop new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.